Patents by Inventor Frank Loganzo

Frank Loganzo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SITE SPECIFIC HER2 ANTIBODY DRUG CONJUGATES
    Publication number: 20200377615
    Abstract: The present invention provides site specific HER2 antibody drug conjugates and methods for preparing and using the same.
    Type: Application
    Filed: June 3, 2020
    Publication date: December 3, 2020
    Applicant: Pfizer Inc.
    Inventors: Dangshe MA, Frank LOGANZO, Jr., Kimberly Ann MARQUETTE, Edmund Idris GRAZIANI, Puja SAPRA, Pavel STROP
  • Site specific HER2 antibody drug conjugates
    Patent number: 10689458
    Abstract: The present invention provides site specific HER2 antibody drug conjugates and methods for preparing and using the same.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: June 23, 2020
    Assignee: Pfizer Inc.
    Inventors: Dangshe Ma, Frank Loganzo, Jr., Kimberly Ann Marquette, Edmund Idris Graziani, Puja Sapra, Pavel Strop
  • SITE SPECIFIC HER2 ANTIBODY DRUG CONJUGATES
    Publication number: 20170151341
    Abstract: The present invention provides site specific HER2 antibody drug conjugates and methods for preparing and using the same.
    Type: Application
    Filed: November 21, 2016
    Publication date: June 1, 2017
    Applicant: Pfizer Inc.
    Inventors: Dangshe MA, Frank LOGANZO, JR., Kimberly Ann MARQUETTE, Edmund Idris GRAZIANI, Puja SAPRA, Pavel STROP
  • COMPOSITIONS AND METHODS FOR MODULATION OF PLK1 KINASE ACTIVITY
    Publication number: 20080279874
    Abstract: Described are compositions and methods for activating a Plk1 protein as well as phospho-specific anti-Myt1 antibodies that can be used to detect phosphorylation of Myt1. Activated Plk1 protein, phospho-specific anti-Myt1 antibodies, and/or Plk1 substrates can be used in screening assays to identify compounds that modulate the ability of Plk1 to phosphorylate and/or bind to a Plk1 substrate.
    Type: Application
    Filed: May 6, 2008
    Publication date: November 13, 2008
    Applicant: Wyeth
    Inventors: Frank Loganzo, JR., Girija Krishnamurthy, Weidong Warren Ding, Xingzhi Cindy Tan, Jagruti Hasmukh Patel
  • Assays to Identify Irreversibly Binding Inhibitors of Receptor Tyrosine Kinases
    Publication number: 20080268460
    Abstract: The present invention relates to a method of identifying an inhibitor of a receptor tyrosine kinase that irreversibly binds to the kinase. Specifically, the method comprises using a variety of assays, either alone or in combination, to identify compounds that irreversibly bind to tyrosine kinases. More specifically, there are four assays, which are novel variations of a basic enzyme assay and identify irreversible binding inhibitors.
    Type: Application
    Filed: May 11, 2005
    Publication date: October 30, 2008
    Applicant: Wyeth
    Inventors: Frank Loganzo, Lee M. Greenberger, Xingshi Tan, Allan Wissner
  • Method of treating resistant tumors
    Publication number: 20040121965
    Abstract: The invention provides a method of treating or inhibiting the growth of or eradicating a tumor in a mammal in need thereof wherein said tumor is resistant to at least one chemotherapeutic agent which method comprises providing to said mammal an effective amount of a compound of Formula II or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 18, 2003
    Publication date: June 24, 2004
    Applicant: Wyeth Holdings Corporation
    Inventors: Lee Martin Greenberger, Frank Loganzo, Carolyn Mary Discafani-Marro, Arie Zask, Semiramis Ayral-Kaloustian